Copaxone and Osteoporosis - a phase IV clinical study of FDA data

Summary:

Osteoporosis is reported as a side effect among people who take Copaxone (glatiramer acetate), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Ampyra, and have Osteopenia.

The phase IV clinical study analyzes which people have Osteoporosis when taking Copaxone. It is created by eHealthMe based on reports of 56,345 people who have side effects when taking Copaxone from the FDA, and is updated regularly.

What is Copaxone?

Copaxone has active ingredients of glatiramer acetate. It is often used in multiple sclerosis. eHealthMe is studying from 56,931 Copaxone users. Check the latest studies of Copaxone.

What is Osteoporosis?

Osteoporosis (bones weak and more likely to break) is found to be associated with 1,806 drugs and 1,905 conditions by eHealthMe. Check the latest studies of Osteoporosis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

56,345 people reported to have side effects when taking Copaxone.
Among them, 100 people (0.18%) have Osteoporosis.

Among these 100 people:

How long have people been on Copaxone when they have Osteoporosis? *

What is the gender of people who have Osteoporosis when taking Copaxone? *

female: 87.5 %
male: 12.5 %

What is the age of people who have Osteoporosis when taking Copaxone? *

What are other drugs people take besides Copaxone? *

What are other side effects people have besides Osteoporosis? *

Joint Pain: 30 people, 30.00%
Fall: 29 people, 29.00%
Fatigue (feeling of tiredness): 23 people, 23.00%
Intervertebral Disc Degeneration (spinal disc degeneration): 18 people, 18.00%
Weight Decreased: 17 people, 17.00%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 16 people, 16.00%
Back Pain: 16 people, 16.00%
Cataract (clouding of the lens inside the eye): 15 people, 15.00%
Headache (pain in head): 15 people, 15.00%
Injection Site Pain: 14 people, 14.00%

What are the existing conditions these people have? *

Osteopenia (a condition where bone mineral density is lower than normal): 22 people, 22.00%
Gait Disturbance: 12 people, 12.00%
Pain: 9 people, 9.00%
Hypoaesthesia (reduced sense of touch or sensation): 6 people, 6.00%
Migraine (headache): 6 people, 6.00%
Abdominal Discomfort: 6 people, 6.00%
Tendonitis (a condition that causes pain and swelling of tendons): 6 people, 6.00%
Immunodeficiency Common Variable: 5 people, 5.00%
Hypersensitivity: 4 people, 4.00%
Joint Pain: 3 people, 3.00%

* Approximation only. Some reports may have incomplete information.

Do you take Copaxone and have Osteoporosis?

- Check whether Osteoporosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Copaxone:

Copaxone (56,931 reports)

Osteoporosis treatments and more:

Osteoporosis (290,735 reports)

Browse all side effects of Copaxone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Osteoporosis:

Osteoporosis (1,806 drugs)

Browse all the conditions that are associated with Osteoporosis:

Osteoporosis (1,905 conditions)

Related publications that referenced our studies

Michaud CJ, Bockheim HM, Nabeel M, Daum TE, "Diagnosis of Exclusion: A Case Report of Probable Glatiramer Acetate-Induced Eosinophilic Myocarditis", Case reports in neurological medicine, 2014 Jul .
Hirschmann S, Gibel A, Tsvelikhovsky I, Lisker A, "Late-Onset Psychosis and Risedronate Treatment for Osteoporosis: A Case Report", Clinical schizophrenia & related psychoses, 2013 May .
Ko KD, Cho BL, "Risedronate-related Localized Amnesia in an Elderly Patient with Osteoporosis", Journal of the Korean Geriatrics Society, 2012 Dec .
Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH, "A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study", PloS one, 2012 Dec .
Hirschmann S, Gibel A, Tsvelikhovsky I, Lisker A, "Late-Onset Psychosis and Risedronate Treatment for Osteoporosis: A Case Report", Clinical schizophrenia & related psychoses, 2013 May .
Michaud CJ, Bockheim HM, Nabeel M, Daum TE, "Diagnosis of Exclusion: A Case Report of Probable Glatiramer Acetate-Induced Eosinophilic Myocarditis", Case reports in neurological medicine, 2014 Jul .
Ko KD, Cho BL, "Risedronate-related Localized Amnesia in an Elderly Patient with Osteoporosis", Journal of the Korean Geriatrics Society, 2012 Dec .
Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH, "A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study", PloS one, 2012 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on glatiramer acetate (the active ingredients of Copaxone) and Copaxone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.